Cardiovascular co-morbidity in rheumatic diseases

Area of Science:

• Rheumatology
• Cardiology
• Immunology

Background:

• Rheumatic disorders significantly increase cardiovascular disease (CVD) risk beyond traditional factors.
• Disease severity in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) is a key CVD risk.
• Inflammation and immune dysregulation are shared mechanisms between rheumatic diseases and atherosclerosis.

Purpose of the Study:

• To review the link between rheumatic disorders and CVD.
• To discuss shared inflammatory pathways as therapeutic targets.
• To outline a research agenda for CVD prevention in rheumatic diseases.

Main Methods:

• Review of recent data on inflammation suppression and CVD risk in RA.
• Analysis of atorvastatin's anti-inflammatory effects in RA.
• Discussion of preventive strategies integrating inflammation insights and lifestyle management.

Main Results:

• Inflammation suppression reduces CVD morbidity and mortality in severe RA.
• Statins, like atorvastatin, demonstrate clinically relevant anti-inflammatory effects.
• Structured preventive strategies are increasingly recognized as necessary.

Conclusions:

• Understanding inflammation's role is crucial for preventing CVD in rheumatic diseases.
• Targeting shared inflammatory pathways offers therapeutic potential.
• Integrated strategies addressing inflammation and lifestyle factors are needed for CVD risk reduction.